Table 3.

Multivariable analysis of prognostic markers in the pooled endocrine-treated patients of the Uppsala (N = 80), Stockholm (N = 114), Oxford (N = 99), and Guys (N = 87) cohorts, N = 380 in total

Histologic grade (N = 324a)Genomic grade (N = 366a)
HR (95% CI)PHR (95% CI)P
Ageb1.67 (0.76–3.70)0.2001.43 (0.69–2.99)0.340
Sizec2.30 (1.39–3.81)0.0012.09 (1.33–3.30)0.002
Nodal Statusd1.30 (0.81–2.07)0.2701.44 (0.94–2.22)0.090
Histologic gradee
 G1ref (—)ref (—)
 G24.11 (1.63–10.34)0.003
 G33.38 (1.26–9.08)0.016
Genomic gradef1.62 (1.29–2.04)<0.001
MV score (continuous)0.70 (0.50–0.97)0.0300.89 (0.65–1.21)0.450
  • NOTE: Patient numbers in each group (total N = 380) Distant metastasis-free survival, HR per 25 increments in MV score.

  • Abbreviation: ref, reference category.

  • aReduced number of patients, missing cases shown below.

  • bAge ≤ 50 years (N = 51) vs. Age > 50 years (N = 329).

  • cSize ≤ 20 mm (N = 177) vs. size > 20 mm (N = 201), missing (N = 2).

  • dNodal status, negative (N = 177) vs. positive (N = 191), missing (N = 12).

  • eHistologic grade, G1 (N = 71) vs. G2 (N = 179) vs. G3 (N = 86), missing (N = 44).

  • fGenomic grade, GG1 (N = 224) vs. GG3 (N = 156).